AFT Pharmaceuticals Limited (AFT.NZ)
NZD 2.65
(1.92%)
NZD 2.65
(1.92%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | 15.6 Million NZD | 46.51% |
| 2023 | 10.65 Million NZD | -46.32% |
| 2022 | 19.84 Million NZD | 155.05% |
| 2021 | 7.78 Million NZD | -38.69% |
| 2020 | 12.69 Million NZD | 622.95% |
| 2019 | -2.42 Million NZD | 80.93% |
| 2018 | -12.72 Million NZD | 30.8% |
| 2017 | -18.38 Million NZD | -53.85% |
| 2016 | -11.95 Million NZD | 7.15% |
| 2015 | -12.87 Million NZD | -1056.6% |
| 2014 | -1.11 Million NZD | -747.09% |
| 2013 | 172 Thousand NZD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 908 Thousand NZD | -90.13% |
| 2024 Q2 | 1.81 Million NZD | 100.0% |
| 2024 Q4 | 6.89 Million NZD | 0.0% |
| 2024 Q3 | 6.89 Million NZD | 279.76% |
| 2024 FY | 15.6 Million NZD | 46.51% |
| 2023 Q3 | 4.55 Million NZD | 213.64% |
| 2023 Q2 | 1.45 Million NZD | 87.84% |
| 2023 FY | 10.65 Million NZD | -46.32% |
| 2023 Q4 | 9.2 Million NZD | 102.06% |
| 2023 Q1 | 773 Thousand NZD | -95.05% |
| 2022 Q1 | 2.12 Million NZD | -67.81% |
| 2022 FY | 19.84 Million NZD | 155.05% |
| 2022 Q4 | 15.6 Million NZD | 100.0% |
| 2022 Q3 | 7.8 Million NZD | 83.89% |
| 2022 Q2 | 4.24 Million NZD | 100.0% |
| 2021 Q2 | 1.19 Million NZD | 100.0% |
| 2021 Q3 | 3.2 Million NZD | 168.54% |
| 2021 Q4 | 6.59 Million NZD | 105.87% |
| 2021 FY | 7.78 Million NZD | -38.69% |
| 2021 Q1 | 596 Thousand NZD | -78.61% |
| 2020 Q1 | 4.95 Million NZD | 1099.27% |
| 2020 Q2 | 9.9 Million NZD | 100.0% |
| 2020 Q4 | 2.78 Million NZD | 210.94% |
| 2020 Q3 | 896 Thousand NZD | -90.95% |
| 2020 FY | 12.69 Million NZD | 622.95% |
| 2019 Q1 | -2.09 Million NZD | 37.92% |
| 2019 FY | -2.42 Million NZD | 80.93% |
| 2019 Q4 | 413 Thousand NZD | 0.0% |
| 2019 Q3 | 413 Thousand NZD | 119.72% |
| 2019 Q2 | -2.09 Million NZD | 0.0% |
| 2018 FY | -12.72 Million NZD | 30.8% |
| 2018 Q2 | -3.43 Million NZD | 0.0% |
| 2018 Q3 | -3.37 Million NZD | 1.85% |
| 2018 Q4 | -3.37 Million NZD | 0.0% |
| 2018 Q1 | -3.43 Million NZD | 6.97% |
| 2017 Q1 | -5.5 Million NZD | 58.54% |
| 2017 Q3 | -3.69 Million NZD | 32.84% |
| 2017 FY | -18.38 Million NZD | -53.85% |
| 2017 Q4 | -3.69 Million NZD | 0.0% |
| 2017 Q2 | -5.5 Million NZD | 0.0% |
| 2016 Q2 | -2.89 Million NZD | 0.0% |
| 2016 FY | -11.95 Million NZD | 7.15% |
| 2016 Q4 | -13.26 Million NZD | -254.97% |
| 2016 Q3 | -3.73 Million NZD | -29.06% |
| 2016 Q1 | -2.89 Million NZD | 14.33% |
| 2015 Q4 | -3.38 Million NZD | 0.0% |
| 2015 Q2 | -3.05 Million NZD | 0.0% |
| 2015 FY | -12.87 Million NZD | -1056.6% |
| 2015 Q3 | -3.38 Million NZD | -10.62% |
| 2015 Q1 | -3.05 Million NZD | 0.0% |
| 2014 FY | -1.11 Million NZD | -747.09% |
| 2013 FY | 172 Thousand NZD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Greenfern Industries Limited | -1.57 Million NZD | 1092.493% |
| Rua Bioscience Limited | -13.71 Million NZD | 213.779% |